Trial ID or NCT#

NCT01617668

Status

not recruiting iconNOT RECRUITING

Purpose

To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression

Official Title

A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Mark Pegram
Mark Pegram
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061